We recently shared a list of the 12 Best Italian Stocks to Buy in 2025. Now, let’s dive into how Genenta Science S.p.A. (NASDAQ:GNTA) compares to these top Italian stocks.
According to Deloitte, the Italian economy saw a slowdown in growth throughout 2024. The service sector grew, but other sectors like manufacturing and automotive struggled. Both consumers and businesses were feeling uncertain, largely because major euro-area economies were also lagging.
In 2024, only the services sector propped up GDP growth, while other areas faced declines. But what does the future hold for Italy’s economy? Inflation has slowed down and remains lower than many other European countries. However, energy costs are still high in Italy compared to nations like France and Germany, which may affect the competitiveness of Italian businesses. Deloitte believes inflation will stay below the euro area’s average in 2025, which might help real wages gradually recover.
Interestingly, though the labor market contracted last year, more people are being employed, even if the total hours worked have dropped, especially in industry. Deloitte predicts that the economy will see modest growth in 2025, in line with other euro-area nations. Meanwhile, BNP Paribas reports that Italy has the second-lowest inflation in the Eurozone, trailing only Ireland. That said, inflation ticked up slightly in January due to less energy deflation.
Post-pandemic, Italy has shown notable recovery and performed well compared to other major Eurozone economies. Despite GDP being significantly above pre-pandemic levels, recent quarterly activity has stalled. Still, private consumption rose in 2024 as confidence improved and inflation declined.
Looking ahead, Allianz Trade anticipates a boost in private consumption due to rising incomes and an easing of monetary policy. They expect more public spending and predict GDP growth of 0.8% in 2025, followed by 1% the next year.
To identify the 12 Best Italian Stocks to Buy in 2025, we used various rankings and selected companies headquartered in Italy that analysts believe have growth potential. These stocks are listed based on their average upside potential as of February 10, with insights from hedge funds drawn from Insider Monkey’s extensive database.
Genenta Science S.p.A. (NASDAQ:GNTA), a clinical-stage biotechnology company based in Milan, focuses on gene therapies for solid tumors. Analyst Jason McCarthy from Maxim Group has a “Buy” rating with a target price of $21.00, citing promising developments in their gene therapy platform, Temferon. This therapy has just received the go-ahead for a Phase 1 trial in metastatic renal cell cancer from the Agenzia Italiana del Farmaco, marking a significant achievement.
Temferon aims to offer new treatment options for patients with advanced renal cancer. Research suggests it can help reshape the tumor environment and activate the immune response against different cancers. Recently, Genenta strengthened its partnership with AGC Biologics to improve its production capabilities, ensuring adherence to rigorous manufacturing standards.
Overall, Genenta Science ranks first on our list of best Italian stocks to buy in 2025. While it shows great promise, investors may find even more undervalued opportunities in the AI sector. If you want to explore investing in a promising AI stock that has a lower price-to-earnings ratio than GNTA, take a look at our report on the cheapest AI stock.
Disclosure: None. This article was originally published on Insider Monkey.
Source link
Deloitte, European economies, moderate inflation, Italian economy, Italian companies, Allianz Trade, Italy, GNTA, consumer inflation
